All-cause mortality rates were similar between hybrid coronary revascularization and conventional CABG, according to the results of a 5-year follow-up of the HYBRID trial, recently published in JACC: Cardiovascular Interventions.
“Conventional CABG is still an evidence-based gold standard in the treatment of patients with multivessel CAD,” Mateusz Tajstra, MD, from the department of cardiology, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland, and colleagues wrote in the study background. “There is a lack of robust clinical data, and available data are mostly limited to observational studies with short-term follow-up. Accordingly, the aim of this study was to evaluate the 5-year clinical outcome for the patient population from the HYBRID study.”
This activity is supported by educational funding provided by Amarin Pharma Inc., Amgen, and Quest Diagnostics.
National Lipid Association Scientific Sessions
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.